Forte Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Forte Biosciences, Inc. (FBRX) on June 2, 2026, regarding events occurring on May 29, 2026. The report details the results of the Company's 2026 Annual Meeting of Stockholders and the approval of an amended equity incentive plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and equity plan amendments rather than financial performance.
Material Changes and Corporate Actions
- Equity Plan Approval: Stockholders approved the Amended and Restated 2021 Equity Incentive Plan (A&R 2021 Equity Incentive Plan). The plan reserves 5,190,000 shares for issuance, comprising 3,340,000 shares from a prior special meeting and 1,850,000 newly requested shares. An additional 44,093 shares may be added from expired or forfeited awards under legacy plans.
- Director Elections: Three Class III directors were elected to serve until the 2029 annual meeting: Steven Kornfeld, Scott Brun, M.D., and Paul A. Wagner, Ph.D.
- Accounting Firm Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: Stockholders approved the advisory vote on executive compensation for the fiscal year ended December 31, 2025.
Voting Results and Shareholder Participation
Of the 20,478,817 shares outstanding as of the April 17, 2026 record date, 17,766,034 shares were represented at the Annual Meeting. Key voting outcomes included:
- Director Elections: Paul A. Wagner received the highest support with 16,027,110 votes for. Steven Kornfeld and Scott Brun received 12,286,043 and 12,958,889 votes for, respectively.
- Equity Plan: Approved with 11,911,879 votes for and 3,997,050 votes against.
- Executive Compensation: Approved with 12,143,153 votes for and 3,764,729 votes against.
- Accounting Firm: Ratified with 17,722,893 votes for and only 3,182 votes against.
Outlook, Risks, and Contingencies
The filing does not contain specific management commentary on future outlook, risks, or contingencies beyond the standard incorporation by reference of the proxy statement for details on the equity plan. The primary purpose of the new equity plan is stated as attracting and retaining personnel and providing incentives.
Key Facts for Investor Verification
- Verify the total share count reserved under the new A&R 2021 Equity Incentive Plan (5,190,000 base shares plus potential additions).
- Review the full text of the Amended and Restated 2021 Equity Incentive Plan filed as Exhibit 10.1 for specific vesting terms and grant conditions.
- Note the significant number of votes withheld or cast against the director elections and executive compensation proposals, indicating potential shareholder dissent.
- Confirm the term of the newly elected Class III directors extends through the 2029 annual meeting.